Tenofovir Alafenamide Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Tenofovir Alafenamide Access in 2026

As a prescriber managing patients with chronic hepatitis B, you're likely aware that Tenofovir Alafenamide (TAF) — marketed as Vemlidy by Gilead Sciences — has become increasingly difficult for patients to fill at retail pharmacies. While this isn't a traditional manufacturing shortage, the practical impact on patient care is real and growing.

This briefing covers the current availability picture, prescribing implications, cost and access barriers, and tools you can use to help your patients maintain uninterrupted antiviral therapy.

Timeline: How We Got Here

Tenofovir Alafenamide was approved by the FDA for chronic hepatitis B in November 2016, offering a significant improvement over Tenofovir Disoproxil Fumarate (TDF) in terms of renal and bone safety profiles. Since then, TAF has become the preferred tenofovir-based option for many patients.

Key developments affecting availability:

• 2016: Vemlidy approved for chronic HBV in adults with compensated liver disease
• 2019: Pediatric indication expanded to patients ≥6 years weighing ≥25 kg
• 2025: Generic Emtricitabine/TAF combination authorized in the EU (Viatris), but no standalone TAF generic reaches the US market
• 2026: FDA has approved generic TAF manufacture, but no US-marketed generic exists. Brand Vemlidy remains the sole US source.

Prescribing Implications

The lack of a US generic and the specialty medication classification of Vemlidy create several prescribing challenges:

Prior Authorization and Step Therapy

Many payers require prior authorization for Vemlidy. Some implement step therapy protocols requiring documented trial of — or medical justification for not using — Tenofovir Disoproxil Fumarate (TDF) before approving TAF. This is particularly relevant for treatment-naive patients.

When submitting prior authorizations, documenting the following can strengthen approval:

• Baseline or declining estimated GFR
• History of or risk factors for osteoporosis/osteopenia
• DXA scan results showing bone mineral density concerns
• Prior TDF intolerance or adverse effects
• Age-related renal risk factors

Specialty Pharmacy Routing

Many insurance plans route Vemlidy prescriptions to designated specialty pharmacies. Prescriptions sent to standard retail pharmacies may be rejected or require manual intervention. Proactively identifying the patient's specialty pharmacy network can prevent delays.

Treatment Interruption Risks

The FDA boxed warning on Vemlidy regarding severe acute exacerbation of hepatitis B upon discontinuation makes treatment continuity critical. When patients report access difficulties, prompt intervention — whether through pharmacy coordination, temporary bridging with an alternative agent, or sample provision — is essential.

Current Availability Picture

As of early 2026:

• FDA shortage status: Vemlidy is not listed on the FDA Drug Shortage Database
• Retail pharmacy stocking: Limited — many chain pharmacies do not routinely stock Vemlidy due to its high cost ($1,500-$1,800/month) and low volume
• Specialty pharmacy availability: Generally reliable through designated specialty pharmacy networks
• Mail-order: Available through most plans' mail-order specialty services
• Generic status: No US-marketed generic. EU generic combination (Emtricitabine/TAF) authorized in 2025 but not available domestically.

Cost and Access Considerations

Understanding the financial landscape helps guide patient counseling:

• Cash price: $1,500-$1,800 for 30 tablets
• Gilead co-pay assistance: Commercially insured patients may qualify for $0 co-pay. Program details at 1-855-769-7284.
• Gilead Advancing Access: Free medication for qualifying uninsured/underinsured patients. Apply at gileadadvancingaccess.com or call 1-800-226-2056.
• 340B pricing: Available at qualifying FQHC and hospital-associated pharmacies
• Alternative agent costs: Generic TDF: $30-$80/month. Generic Entecavir: $30-$100/month.

For a detailed patient-facing cost guide you can share, see how to save money on Tenofovir Alafenamide.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder for Providers allows you and your staff to check real-time pharmacy availability for Tenofovir Alafenamide. This can be integrated into your prescription workflow to proactively identify pharmacies with stock before the patient leaves your office.

Alternative Agent Reference

When TAF is unavailable and a bridge or switch is needed, these are the primary alternatives for chronic HBV:

• Tenofovir Disoproxil Fumarate (TDF/Viread): 300 mg daily. Generic available. Monitor renal function and bone density more closely. Most direct pharmacologic equivalent.
• Entecavir (Baraclude): 0.5 mg daily (treatment-naive) or 1 mg daily (lamivudine-resistant). Generic available. Preferred in patients with renal concerns who cannot tolerate either tenofovir formulation.
• Lamivudine (Epivir-HBV): 100 mg daily. High resistance rates limit long-term monotherapy use. Consider only for short-term bridging or combination regimens.

For a patient-facing version of this information, see alternatives to Tenofovir Alafenamide.

Looking Ahead

Several developments may improve the TAF access landscape:

• US generic entry: With FDA approval already granted for generic manufacture, a US-marketed generic TAF product could emerge in 2026-2027, though timing remains uncertain.
• Pipeline agents: Novel HBV treatments targeting functional cure are in Phase II/III trials, though none are expected to reach market before 2027-2028.
• Policy changes: Growing attention to specialty medication access may drive payer and PBM policy adjustments.

Final Thoughts

While Tenofovir Alafenamide is not in a formal shortage, the practical barriers to access — specialty pharmacy routing, prior authorization requirements, lack of a US generic, and limited retail stocking — create real challenges for patients managing chronic hepatitis B.

Proactive prescribing practices, familiarity with Gilead's patient assistance programs, and tools like Medfinder for Providers can help minimize treatment interruptions. For a practical guide on workflow integration, see our companion post on how to help your patients find Tenofovir Alafenamide in stock.